Shanghai - Delayed Quote CNY

RemeGen Co., Ltd. (688331.SS)

92.06 -1.56 (-1.67%)

At close: October 30 at 3:00:00 PM GMT+8

RemeGen (SEHK:9995) Stock Faces Q3 Earnings Doubts Despite Profit Swing

Simply Wall St. 1d ago

688331.SS
-1.67%
9995.HK
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

GlobeNewswire 9d ago

688331.SS
-1.67%
VOR
RemeGen (SEHK:9995) Stock Looks Reasonable After Its 78% Three Year Run

Simply Wall St. 12d ago

688331.SS
-1.67%
9995.HK
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

GlobeNewswire 1mo ago

688331.SS
-1.67%
VOR

9995.HK
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

GlobeNewswire 4mo ago

688331.SS
-1.67%
VOR

9995.HK
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

GlobeNewswire 5mo ago

688331.SS
-1.67%
VOR

9995.HK
Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

GlobeNewswire 5mo ago

688180.SS

688331.SS
-1.67%
1877.HK
Chinese and Foreign Translators and Media Figures Discuss New Drivers of Yantai's Development

PR Newswire 3d ago

688331.SS
-1.67%
Chinese and Foreign Translators and Media Figures Discuss New Drivers of Yantai's Development

PR Newswire 3d ago

688331.SS
-1.67%
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight

GlobeNewswire 6mo ago

NOVN.SW

RNAC

MRK.DE
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

GlobeNewswire 4mo ago

688331.SS
-1.67%
VOR

9995.HK
Vertex Pops On 'Remarkable' Results For Chronic Kidney Disease Drug

Investor's Business Daily 7mo ago

VRTX

688331.SS
-1.67%

U.S. markets closed

RemeGen Co., Ltd. (688331.SS)

RemeGen (SEHK:9995) Stock Faces Q3 Earnings Doubts Despite Profit Swing

Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

RemeGen (SEHK:9995) Stock Looks Reasonable After Its 78% Three Year Run

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

Chinese and Foreign Translators and Media Figures Discuss New Drivers of Yantai's Development

Chinese and Foreign Translators and Media Figures Discuss New Drivers of Yantai's Development

Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight

Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

Vertex Pops On 'Remarkable' Results For Chronic Kidney Disease Drug